A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II
Dose (RP2D), pharmacodynamic, and clinical activity of MK-8033.
Parts A and B of the study will determine the maximum tolerated dose (MTD) and RP2D. Part C
of the study will be a single panel crossover study to determine the effect of omeprazole, a
gastric pH modifier, on the pharmacokinetics of MK-8033.